# RWHAP and the Opioid Epidemic: Outcomes of an Opioid Technical Expert Panel

December 12, 2018

4:00 - 5:30 PM

Antigone Dempsey, Elise Young, and Glenn Clark HIV/AIDS Bureau (HAB) Health Resources and Services Administration (HRSA)





# Health Resources and Services Administration (HRSA) Overview

• Supports more than 90 programs that provide health care to people who are geographically isolated, economically or medically vulnerable through grants and cooperative agreements to more than 3,000 awardees, including community and faith-based organizations, colleges and universities, hospitals, state, local, and tribal governments, and private entities

• Every year, HRSA programs serve tens of millions of people, including people living with HIV/AIDS, pregnant women, mothers and their families, and those otherwise unable to access quality health care





# HRSA HIV/AIDS Bureau (HRSA HAB)

### Vision

Optimal HIV/AIDS care and treatment for all.

### **Mission**

Provide leadership and resources to assure access to and retention in high quality, integrated care, and treatment services for vulnerable people living with HIV/AIDS and their families.





## HRSA's Ryan White HIV/AIDS Program (RWHAP)

- Provides comprehensive system of HIV primary medical care, medications, and essential support services for low-income people living with HIV (PLWH)
  - More than half of people living with diagnosed HIV in the United States more than 550,000 people receive care through the Ryan White HIV/AIDS Program
- Funds grants to states, cities/counties, and local community based organizations
  - Recipients determine service delivery and funding priorities based on local needs and planning process
- Payor of last resort statutory provision: RWHAP funds may not be used for services if another state or federal payer is available
- 84.9% of Ryan White HIV/AIDS Program clients were virally suppressed in 2016, exceeding national average of 60%






# RWHAP and the Opioid Epidemic: Outcomes of an Opioid Technical Expert Panel

**Background and Data** 






# Viral Suppression among RWHAP Clients, by State, 2010 and 2016—United States and 2 Territories<sup>a</sup>







# Ryan White HIV/AIDS Program Clients Aged ≥13 Years with HIV Infection Attributed to Injection Drug Use, 2016—United States and 3 Territories<sup>a</sup>






Data represent clients who reported injection drug use as their transmission risk category data may not reflect current behavior.



<sup>&</sup>lt;sup>a</sup> Guam, Puerto Rico, and the U.S. Virgin Islands.

b Includes male-to-male sexual contact, heterosexual contact, perinatal infection, hemophilia, blood transfusion, male-male sexual contact and injection drug use, and any sexual contact among transgender persons including sexual contact and injection drug use.

# Viral Suppression among Clients with HIV Infection Attributed to Injection Drug Use Aged ≥13 Years Served by the Ryan White HIV/AIDS Program, 2016—United States and 3 Territories<sup>a</sup>



IDU, injection drug use.

Data represent clients who reported injection drug use as their transmission risk category; data may not reflect current behavior. Data do not include male-to-male sexual contact and injection drug use nor sexual contact and injection drug use among transgender clients.

N represents the total number of clients in the specific subpopulation.

Viral suppression is defined as ≥1 OAHS visit during the calendar year and ≥1 viral load reported, with the last viral load result <200 copies/mL.

<sup>a</sup> Guam, Puerto Rico, and the U.S. Virgin Islands.





### **HRSA RWHAP Behavioral Health Services**

	Providers (N=1,550)*		Clients (N=551,567)		Total Client Visits
Service category	N	%	N	%	N
Mental health	613	39.5	68,684	12.5	353,896
Any substance abuse – outpatient or residential	278	17.9	20,228	3.7	
Substance abuse - outpatient	257	16.6	19,152	3.5	173,926
Substance abuse - residential	37	2.4	1,329	0.2	



\*Number of providers that provided any service in the given year. Note, total number of funded providers: 2,164 (2016)



# RWHAP and the Opioid Epidemic: Outcomes of an Opioid Technical Expert Panel

**Expert Panel Overview and Key Questions** 





# **Key Framing Questions**

- 1. What are the successes/facilitators, barriers/gaps, and opportunities for addressing opioid addiction in the context of the RWHAP?
- 2. What barriers and facilitators exist at the clinic level for addressing opioid addiction needs for RWHAP clients and patients?
- 3. What are the barriers and facilitators that exist at the EMA/TGA and state levels to address the opioid crisis in metropolitan areas, state jurisdictions, and rural areas?





# **Technical Expert Panel – Community**

**Fred Brason** 

**Project Lazarus** Moravian Falls, NC

**Daniel Daltry** 

Vermont Department of Health Burlington, VT

Judith Feinberg, MD

West Virginia University Morgantown, WV

Marwan Haddad, MD

Community Health Center Middletown, CT

**Rick Hardwood** 

National Association of State Alcohol and Drug Abuse Directors Washington, DC

Pamposh Kaul, MD

Ohio Regional AETC Cincinnati, OH

**Taanya Mannain LISW-CP** 

Little River Medical Center Little River, SC

**Geetika Nadkarni, MPH** 

The Association of State and Territorial Justin Trevino, MD **Health Officials** Arlington, VA

**Daniel Raymond** 

Harm Reduction Coalition New York, NY

Pam Sylakowski

Metro Public Health Department Nashville, TN

**Coleman Terrell** 

Philadelphia Department of Public Health Philadelphia, PA

Alice Thornton, MD

Bluegrass Cares Clinic Louisville, KY

Ohio Department of Mental Health and Addiction Services Columbus, OH

**Emily Zarse, MD** 

Eskenazi Health Centers Indianapolis, IN





# **Technical Expert Panel – HRSA Participants**

**CAPT Sophia Russell**Bureau of Health Workforce Health Resources and Services Administration

**CAPT Christopher Bersani, PsyD**Office of Regional Operations Health Resources and Services Administration

#### Michael Blodgett

Federal Office of Rural Health Policy Health Resources and Services Administration

**Aaron Lopata, MD**Maternal and Child Health Bureau **Health Resources and Services** Administration

#### **Alexander Ross, ScD**

Office of Planning, Analysis and **Evaluation** Health Resources and Services Administration

#### Judith Steinberg, MD, MPH

Bureau of Primary Health Care Health Resources and Services Administration

#### **HRSA HAB Sponsoring Participants**

Stacy Cohen, MPH
Division of Policy and Data
HIV/AIDS Bureau Health Resources and Services Administration

**Antigone Dempsey, MEd**Division of Policy and Data HIV/AIDS Bureau Health Resources and Services Administration

#### Heather Hauck, MSW, LICSW

HIV/AIDS Bureau Health Resources and Services Administration

#### Marlene Matosky, MPH, RN

Division of Policy and Data HIV/AIDS Bureau Health Resources and Services Administration

#### **HRSA HAB Behavioral Health Workgroup**

CAPT Elise Young, LICSW, DCSW - Chair Glenn Clark, MSW - Chair





# **Technical Expert Panel – Federal Partners**

#### Danae "Dee" Bixler, MD

Division of Viral Hepatitis Centers for Disease Control and Prevention

#### John Brooks, MD

Division of HIV/AIDS Prevention Centers for Disease Control and Prevention

#### **Humberto Carvalho**

Addiction Technology Transfer Centers Substance Abuse and Mental Health Services Administration

#### **Steve Daviss, MD**

Office of the Chief Medical Officer Substance Abuse and Mental Health Services Administration

#### Senad Handanagic, MD, MPH

Division of HIV/AIDS Prevention Centers for Disease Control and Prevention

#### Anne Herron, MS

Division of Regional and National Policy Liaison Substance Abuse and Mental Health Services Administration Richard Jenkins, PhD Prevention Research Branch National Institute on Drug Abuse

#### Chideha Ohuoha, MD

Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration

#### **Gerlinda Somerville**

Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration


#### CDR Meena Vythilingam, MD

Office of the Assistant Secretary for Health






# Overdose Deaths per 100,000 in the United States 1999-2015








### Overdose Deaths in the United States 2015








# **United States Prescribing Rates by State 2016**







# Overdose Deaths Involving Opioids, by Type of Opioid, United States, 2000-2016








# **2015 Reported Law Enforcement Fentanyl Encounters**

- No reports
- 0 to 50
- 50 to 99
- 100 to 249
- **250** to 499
- 500 or more







# RWHAP and the Opioid Epidemic: Key Themes





### **Barriers for PLWH with OUD**

- RWHAP and OUD: Defining the Patient Population and Data Gaps
- Stigma Related to Opioid Use
- Negative Attitudes Toward MAT
- Need for Increased Clinical Training Regarding OUD
- Workforce Shortages





# **Facilitators to Support PLWH with OUD**

- Leveraging telemedicine
- Systems approach across sectors
- Housing, transportation, and food supports
- Using peers in a transformational ways (mutual aid and support)
- Education and training for all clinical staff from registration to staff nurse practitioners, and physician assistants
- Innovative strategies for working with active addiction



### **Contact Information**

**Antigone Dempsey** 

**Director, Division of Policy and Data** 

**HIV/AIDS Bureau (HAB)** 

**Health Resources and Services Administration (HRSA)** 

Email: adempsey@hrsa.gov

Phone: 301-443-0360


Web: <u>hab.hrsa.gov</u>





### To learn more about our agency, visit

www.HRSA.gov



FOLLOW US: (f) (in)











